Gastrin-releasing peptide (GRP), a bombesin-like peptide, is an autocrine or paracrine growth factor that can stimulate the growth of various cancer cells, making it an ideal target antigen to develop vaccines against cancer. In this study, we developed a novel DNA vaccine that encodes six tandem repeats of B-cell epitope GRP 18À27 (GRP6) flanked by HSP65 as carrier and four tandem repeats of mycobacterial HSP70 407À426 (M4) as helper T-cell epitopes for enhancement of immunogenicity. When intramuscularly immunized to mice, this anti-GRP DNA vaccine-induced GRP-specific antibody (Ab) responses that were at least 10-fold higher in magnitude compared with HSP65-GRP6 protein vaccine. Both prophylactic and therapeutic antitumor immunities induced by vaccination significantly suppressed the growth of GRP-dependent prostate carcinoma RM-1 in vivo and prolonged the survival of tumor-inoculated mice. Out results also showed that the immune sera with high titer of GRP-specific Abs effectively inhibited the growth of tumor in mice and dose dependently inhibited proliferation of cultured RM-1 cells in vitro, suggesting that the GRP neutralizing Ab is responsible for the protective and therapeutic antitumor activity of vaccination. These findings may be of great importance in the further exploration of the applications of growth factors identified in human in cancer therapy.
Introduction
Gastrin-releasing peptide (GRP) is a member of the family of bombesin-like peptides that functions as a gastrointestinal hormone and neurotransmitter in mammals including humans. In recent years, GRP has been shown to be a potent mitogen for a variety of tumors including pancreatic, small cell lung, prostate, renal and breast cancer. 1 GRP has an important role in human cancers exerting autocrine, paracrine or endocrine growth factor effects. 2 The GRP receptor (GRPR) is expressed aberrantly in various cancer cells 1 and GRP binding appears to activate multiple cellular signaling pathways resulting in cellular proliferation and tumor formation. 3, 4 These observations inspire researchers to find suitable approach to treat cancers by taking advantage of blocking the GRP to GRPR signal pathway. Various kinds of GRPR antagonist, such as peptide antagonists RC-3095 and RC-3940-II 5 as well as nonpeptide antagonists PD176252 and PD168368, 6, 7 have been developed to inhibit the growth of different cancers.
Others have shown that a mouse monoclonal antibody (Ab) 2A11 against GRP is able to block proliferation of small cell lung cancer cell lines. 8 In addition, such cytotoxic peptide conjugates as doxorubicin-bombesin conjugates 9 and camptothecin-bombesin conjugates 10 have also shown impressive antitumoral activity.
Hormone and growth factor deprivation have been therapeutically achieved up to now by surgical, radiation and chemical means. However, the immune system usually can be manipulated to recognize hormones and growth factors. The idea of inducing a deprivation of hormones and growth factors by active immunizations is appealing, and initial evidence regarding the feasibility of this approach for cancer treatment is starting to appear in the literature. 11 This immunological deprivation approach targeting GRP, which can act as growth factor in many types of cancers, may also create the possibility of chronic management for GRP-dependent cancer treatment.
We have shown earlier that a chimeric protein vaccine targeting GRP effectively inhibited the growth of a GRPdependent breast cancer in vivo. 12 However, DNA-based vaccination targeting GRP might offer several potential advantages over the conventional protein vaccines because DNA vaccines are relatively simple and inexpensive to produce in pure form and may allow the extension of the technology to non-industrialized nations. 13 Although DNA-based vaccines hold great promise because of their ease of production, safety and stability, the immunogenicity of DNA-based vaccines is not as great as might be hoped. 14 To induce robust Ab response, multiple strategies have been used, including representation of self-epitope as tandem arrays, linkage of potent molecular adjvants and DNA-prime proteinboost vaccination. 15 Even if these strategies were applied, it was unfortunate as the DNA vaccine would not have to be administered as a therapeutic vaccine in real life probably because of the still relatively low immunogenicity of DNA vaccine. The current investigation is focusing on the construction of novel anti-GRP DNA vaccines with increased immunogenicity and antitumor activity. To break the tolerance of this self-peptide and induce specific deprivation of GRP by strong humoral immune response in vivo, six copies of the B-cell epitope GRP 18À27 16 in linear alignment (GRP6) have been inserted in an eukaryotical expression vector (pCR3.1) as immunogen. In addition, mycobacterial heat shock protein 65 kDa (HSP65) was constructed upstream of GRP6, serving as vector for delivering this B-cell epitopes. 17 Moreover, tandem repeats (1-4) of mycobacterial HSP70 fragment 407-426 18 in linear alignment was inserted into the DNA vaccine downstream of GRP immunogen to analyze whether introduction of this foreign T-helper epitope into DNA vaccine could boost GRP immunogenicity by inducing strong neutralizing auto-Abs against the tumor growth factor sufficiently to be protective in tumor cell challenge.
Results

GRP immunogenicity relies on the introduction of foreign T-helper epitopes.
To analyze whether DNA vaccines containing six copies of GRP 18À27 could evoke strong humoral immune response, we compared the levels of GRP-specific IgG in the sera collected from immunized mice by ELISA (Figure 2a ). All GRP-based DNA vaccines, as compared with the control vaccine (p-HSP65-M2) or PBS control, greatly increased titers of specific anti-GRP Abs 5 weeks post-immunization. Among the GRP-based vaccines, the anti-GRP Ab titers in mice immunized with the plasmid containing two or four copies of the mycobacterial HSP70 407À426 gene (M) were the highest especially at 9 weeks post-immunization (Po0.001). These data clearly showed that two or four copies of M gene were highly potent in augmenting humoral response and immunogenicity of the anti-GRP vaccine.
The specificity of anti-GRP Abs elicited in immunized mice was established by immunoblots using the recombinant GFP-GRP10 protein as antigen 12 (data not shown). Specific anti-HSP65 Abs were also detected by immunoblots using purified HSP65 as antigen 19 (data not shown).
In addition, the expression level of anti-GRP DNA vaccine containing one or three copies of the M gene did not show significant difference as compared with the one containing two or four copies of the M gene (Figure 1b) , showing the low immunogenicity of plasmid containing one or three copies of the M gene was not caused by the low expression of hGRP chimeric protein.
Induction of prophylactic antitumor immunity. To analyze the protective effect of DNA vaccines against prostate carcinoma, C57BL/6 male mice were i.m. vaccinated with 50 mg per mouse plasmid DNA or PBS biweekly at weeks 1, 3 and 5. One week after the last immunization, mice were inoculated with 2 Â 10 5 RM-1 cells. Tumor dimensions were measured every other day and mice were killed and solid tumors were excised and weighted at day 21 after tumor cell challenge. As shown in Figure 2b , vaccination with p-HSP65-GRP6-M2 and p-HSP65-GRP6-M4 significantly retarded RM-1 tumor growth. Tumor volumes of p-HSP65-GRP6-M2 and p-HSP65-GRP6-M4 immunized mice on day 21 after tumor inoculation were only 29% and 12% of those of PBS-treated group, respectively, and the mean weight of excised tumors on day 21 showed similar results ( Figure 2c ). No significant inhibition of tumor growth was observed in groups treated with other four plasmid DNA.
Tumors from PBS, p-HSP65-GRP6-M2 or p-HSP65-GRP6-M4-treated mice were dissected and fixed for histologic analysis. The tumor sections from p-HSP65-GRP6-M2 and p-HSP65-GRP6-M4-treated mice showed severe hemorrhage and necrosis (necrosis was very extensive, occupying the whole tumor even to the peripheral region of tumor tissue). In contrast, these phenomena were not present in tumor sections from animals injected PBS, in which tumor cells were highly proliferative and blood vessels were intact (Figure 2d ). In addition, DNA plasmid vaccinated mice had no noticeable changes in fur, body weight, behavior, feeding or life span. No significant pathologic changes were found in liver, lung, heart, kidney, small intestine, spleen or prostate by histopahtological examination (Figure 3 ). This suggested that the immunization was apparently harmless to normal mice.
Effects of GRP 1À17 and anti-GRP Abs on the proliferation of RM-1 cells in vitro. RM-1 cells cultured in vitro were exposed to various concentrations of GRP 1À17 , anti-GRP Abs and GRP anti-sera, and the effects on the cell proliferation were determined by MTT assay. GRP 1À17 at 0.01 mM to 10 mM (Po0.01) increased cell proliferation by 27.8% to 57.9%, whereas anti-GRP Abs at 1.56 mg ml -1 to 50 mg ml -1 (Po0.05) inhibited cell proliferation by 19.7 to 43.3%, compared with controls (Figures 4a and b) . Moreover, confluent RM-1 cells on coverslips were strongly stained by the purified anti-GRP Abs and anti-GRPR Abs, as shown in Figure 4d , but were not by control Abs (data not shown).
When up to 45% of sera were included in the culture medium, the immune sera from p-HSP65-GRP6-M2 and p-HSP65-GRP6-M4 immunized mice dose dependently inhibited proliferation of RM-1 cells in vitro, whereas the pre-immune sera or anti-sera from other DNA vaccine immunized mice caused o10% inhibition on the proliferation of RM-1 cells (Figure 5a ). Furthermore, cultured RM-1 cells exposed to 12.5 and 50 mg ml -1 anti-GRP Abs induced apoptotic cells up to 18 and 24% (Figure 4c ).
In addition, the anti-GRPR Abs but not the anti-GRP Abs showed complement-induced Ab-dependent cell damage to RM-1 cells (Figure 5e ), probably because of the GRP is not a transmembrane protein/peptide located on the cell surface.
The immune sera inhibited tumor growth in mice. To analyze the mechanism of antitumor effect of the DNA vaccination targeting GRP, the immune sera were Study on T-cell-mediated immune response targeting GRP. Although the target sequence chosen in this study is a B-cell epitope, the potential T-cell epitopes in this region of GRP might also exist. With this hypothesis, the T-cellmediated immune responses induced by anti-GRP vaccines have been test in vitro. Splenocytes isolated from mice immunized with p-HSP65-GRP6-M4 induced strong splenocyte proliferation after stimulation with Con A, but not with hGRP 18À27 (Figure 5c ). The following CTL assays also showed negative results that T lymphocytes from immunized mice were not cytotoxic to cultured RM-1 cells in vitro, or inhibited tumor growth when intravenously injected to tumor-implanted mice (Figures 5b and d ). All these results showed that T-cellmediated immune response targeting GRP was not induced after immunization.
Prolongation of survival by prophylactic antitumor immunity. C57BL/6 male mice were i.m. vaccinated with 50 mg per mouse plasmid DNA (p-HSP65-GRP6-M2 and p-HSP65-GRP6-M4) or PBS biweekly at weeks 1, 3 and 5. Another group of mice were s.c. immunized with 50 mg per mouse HSP65-GRP6 protein biweekly at weeks 1, 3 and 5. One week after the last immunization, mice were inoculated with 2 Â 10 5 RM-1 cells. Tumor dimensions of each treated group were measured every other day until the first mouse died. As shown in Figure 6a , it was found that vaccination with all of the three vaccines targeting GRP significantly retarded RM-1 tumor growth. Survival analysis was performed using the Kaplan-Meier method, with log-rank tests for comparison of survival curves, which is a plot of the percent survival as function of time (Figure 6b) . A significant prolongation effect of all the three vaccines on survival has been observed. The average survival of PBS, HSP65-GRP6, p-HSP65-GRP6-M2 and p-HSP65-GRP6-M4-treated mice were 28, 35, 42 and 51 days, respectively. The number of surviving mice in p-HSP65-GRP6-M4-treated group was three at the end of the experiment (day 60). Unexpectedly, p-HSP65-GRP6-M4 immunization significantly (Po0.05) prolonged the life span of tumor cell inoculated mice even as compared with HSP65-GRP6 protein and p-HSP65-GRP6-M2 immunization.
To further analyze the relationship between the tumor rejection and the Ab titers and avidity, ELISA for titers and avidity assays were performed on anti-sera from mice (n ¼ 8, week 9). As shown in Figure 6c , the average titers against GRP rank as p-HSP65-GRP6-M44p-HSP65-GRP6-M24HSP65-GRP64p-HSP65-GRP6. The mean relative avidity of Abs in the group vaccinated with p-HSP65-GRP6-M2 and p-HSP65-GRP6-M4 was significantly higher than that from the group immunized with HSP65-GRP6 or p-HSP65-GRP6 (Figure 6d) . A comparison of the immune response and development of RM-1 tumor showed that, while the anti-GRP Abs level remained high enough, the tumor growth was inhibited, and vice versa. All these data, again, clearly showed that two or four copies of HSP70 407À426 gene were highly potent in augmenting humoral response and immunogenicity of the anti-GRP vaccine.
Interestingly, the Ab response to GRP was superior to the carrier protein HSP65 when plasmids encode for two or four copies of HSP70 407À426 gene. It appears that the reduced humoral responses to the carrier protein may allow a greater portion of the immune response to be directed to the therapeutically relevant portion of the vaccine (Figure 6c) .
Induction of the therapeutic antitumor immunity. More relevant to the treatment of tumor by vaccines is the therapeutic potential vaccines. For the tumor therapy experiments, C57BL/6 mice (eight per group) were s.c. injected with 1.5 Â 10 4 per mouse RM-1 cells on day 0, and then i.m. immunized with 50 mg per mouse plasmid The therapeutic antitumor immunity was also tested in a therapeutic setting with established lung metastases. C57BL/6 mice (six per group) were intravenously injected with 1.0 Â 10 5 per mouse RM-1 cells on day 0, and then i.m. immunized with 50 mg per mouse plasmid DNA (p-HSP65-M2 and p-HSP65-GRP6-M4) on day 3, 9 and 15, while negative control mice were given PBS. Mice were killed on day 30 and lungs were harvested for measurement of lung weights. Significantly fewer metastases (data not shown) and lower lung weight increase were observed in p-HSP65-GRP6-M4-treated group compared with other groups (Po0.5, Figure 7c ).
Discussion
In this study, we developed a novel DNA vaccine with a plasmid vector to deliver the immunogen of six copies of the B-cell epitope GRP 18À27 . When fused to the carrier protein HSP65, the elevated immunogenicity of GRP epitopes was achieved by the addition of four tandem repeats of mycobacterial HSP70 407À426 (M4) to the vaccine construct as T-helper epitopes. When immunized with p-HSP65-GRP6-M4, a high titer of GRP-specific Abs was detected from the sera of immunized mice. In addition, this type of vaccine evoked both preventive and therapeutic antitumor effects in RM-1 prostate carcinoma, the growth of which has been shown to be regulated by both GRP and mAb in vitro. More importantly, both the preventive and therapeutic antitumor immunity induced by p-HSP65-GRP6-M4 may not only result in significant local growth suppression characterized by the average wet weight of tumor mass but also a significant prolongation of survival. This potent anti-GRP DNA vaccine might provide a supplement to standard surgical Our results have shown the lacking of CTL response does not hamper the effective retarding of tumor growth and prolongation of survival of tumor-implanted mice by vaccination. However, it is clear that the humoral immune response has been elicited by the vaccination with high titer of GRP-specific Abs detected. This phenomenon suggests that GRP-specific Abs may neutralize the self-peptide GRP and lower the concentration of GRP in tumor circumstances, for the activation of GRPR may be interrupted and the successive signal pathway can be blocked. Our results have shown that the immune sera isolated from p-HSP65-GRP6-M4 immunized mice effectively inhibited the growth of tumor in mice and dose dependently inhibited proliferation of cultured RM-1 cells in vitro, whereas little effect on the proliferation of RM-1 cells was observed when using the pre-immune sera or sera with low titers of anti-GRP Abs. Furthermore, cultured RM-1 cells exposed to GRPspecific Abs results in inhibition of cell growth rate as well as apoptotic cell death. This strategy of exploiting GRP auto-Abs to block the GRP/GRPR autocrine or paracrine loop reduces the growth rate of GRP-dependent tumors, and can be classified into therapeutic interventions aiming to deprive cancer cells of their dependent hormone or growth factor, as reviewed by Gonzalez et al. 11 These vaccines have been designed with a different purpose: to activate an Ab immune response against self-hormones and/or growth factors that participate in the stimulation of tumor growth. Clinical trials have been initiated using immunization with human chorionic gonadotrophin, gastrin, gonadotropinreleasing hormone and epidermal growth factor. Preliminary data already show that both the Ab titers and the decrease in the hormone level are related to survival. This completely different mechanism of action could not only stop tumor growth, but could shift the balance between uncontrolled cell proliferation and cell death. So, these vaccines are not meant to destroy the tumor by inducing immune effectors mechanisms, but to re-set the cell proliferation rate below tumor cell death rate, resulting in inhibition of further tumor cell growth.
In mice, although DNA vaccines might readily induce strong cell-mediated immunity, Ab responses are typically weaker than that of corresponding protein-based vaccines. 20 However, p-HSP65-GRP6-M4-induced GRPspecific Ab responses that were at least 10-fold higher in magnitude compared with HSP65-GRP6 protein vaccine. This increased immunogenicity of DNA-based GRP vaccine might result from the introduction of T-helper epitope HSP70 407À426 , which was identified as a major epitope stimulating tumor necrosis factor-a, interleukin-12, and CC chemokine ligand (CCL)-5 in monocytes and dendritic cells in mHSP70. 18 Interestingly, plasmids encoding one or three HSP70 407À426 failed to enhance the immunogenicity of GRP, while plasmids encoding two and four HSP70 407À426 generate the moderate and the highest stronger immune stimulatory potential, respectively. The great enhanced immunogenicity of p-HSP65-GRP6-M4 was unexpected and surprising, and the strongest immune stimulatory potential might not suppose to be limited to the one encoding four tandem repeats of HSP70 407À426 . Findings have previously indicated that tandem repeats and molecular environment of an epitope may dramatically affect its immunogenicity, and in accordance, fusion proteins design should optimally meet with the intracellular processing requirements to greatly augment the efficacy of peptide-based vaccines. 21 The phenomenon in the present work can be supposed to that hGRP fusion protein with four copies of the T-helper epitope HSP70 407À426 arranged as tandem repeats was effectively processed and presented by both B cells and macrophages. The exact mechanism under this phenomenon is now being evaluated as an important subject in our following research. However, the current results have already shown that four HSP70 407À426 is an efficient molecular adjuvant for developing GRP vaccines and might be also useful for self-epitope-based vaccine design. 5 RM-1 cells on day 0 and vaccinated on day 3, 9 and 15, respectively. The experiment was terminated on day 30 and lung weight increase was calculated by using the formula: lung weight increase (%) ¼ (tumor lung weight-normal lung weight)/normal lung weight Â 100. Top, lung weight increase; bottom, representative lungs. A significantly lower lung weight increase was observed in p-HSP65-GRP6-M4-treated group compared with other groups (Po0.5). Notes: values are means±s.d., *Po0.5.
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Materials and methods
Animals
Studies were performed in C57BL/6 male syngenic mice (5-6 weeks old) purchased from Jiangsu Experimental Animal Center (Yangzhou, Jiangsu Province, China). They were maintained in a specific pathogen-free environment throughout the experiments (20-25 1C constant room temperature, 35-40% constant humidity) and fed with clean laboratory rodent diet and drinking water.
Tumor cell lines
The RM-1 cell line derived from the mouse prostate reconstitution model system was ordered from American Type Culture Collection. Cells were maintained in RPMI-1640 (GIBCO, Ontario, Canada) containing 10% fetal calf serum. All media were supplemented with penicillin and streptomycin. RM-1 cells were cultured at 37 1C in a humidified incubator in an atmosphere of 5% CO 2 in air. To establish solid tumor models, 0.2 ml of viable RM-1 cells was inoculated subcutaneous (s.c.) at the right armpit of mice. RM-1 lung metastasis models were established by intravenous injection with 1.0 Â 10 5 viable RM-1 cells to mice.
Construction of DNA vaccines. Plasmid pCR3.1 (Invitrogen Corp., Carlsbad, CA, USA) containing eight 5 0 -GACGTT-3 0 CpG motifs was used as backbone for the construction of the DNA vaccines. DNA fragment encoding HSP65-GRP6 was PCR amplified from pET28a-HSP65-GRP6 template as described earlier. 12 DNA fragments encoding the VEGF183 signal peptide (VS) and mycobacterial HSP70 407À426 were chemically synthesized. The VS complementary DNA was inserted downstream of the cytomegalovirus promotor (pCMV), followed sequentially by the genes encoding for HSP65-GRP6. Tandem repeats (from one to four) of HSP70 407À426 gene (M) were then placed downstream of GRP6. These resulted in the following five DNA vaccines listed as following (Figure 1a ): p-HSP65-GRP6, p-HSP65-GRP6-M1, p-HSP65-GRP6-M2, p-HSP65-GRP6-M3 and p-HSP65-GRP6-M4. Plasmid DNA lacking the GRP6 genes (p-HSP65-M2) served as vaccine control. All constructed DNA vaccines and control were verified by DNA sequencing.
Recombinant fusion protein vaccine targeting GRP
The vector carrying gene encoding for HSP65-GRP6 (pET28a-HSP65-GRP6) was used to transform the Escherichia coli BL21 and the method for expression and purification of the recombinant HSP65-GRP6 was similar to that described by Yankai et al. 22 Briefly, the recombinant engineering bacteria were induced at A 550 of 1.3-1.5 by addition of lactose to a final concentration of 5 mM for 6 h. After then, the bacterial were harvested and lysed for releasing of the recombinant protein. The supernatant fraction containing soluble recombinant protein was precipitated with 5-20% saturated ammonium sulfate and further purification was carried out using chromatographic column of DEAE-cellulose (Whatman, Springfield, UK) and Sephadex G-100 (Pharmacia, Uppsala, Sweden). The purified protein was stored at À20 1C after being lyophilized.
Immunization procedure. Plasmid DNA used for immunization was purified using Qiagen Plasmid Mega Kit (Qiagen, Hilden, Germany) and suspended in phosphate-buffered saline (PBS) at a concentration of 0.5 mg ml -1 . A total of eight C57BL/6 male syngeneic mice were used for each experimental group (one group for each of the six plasmid DNA and PBS control). Mice were anesthetized via intramuscular (i.m.) injections in the anterior thigh with 100 ml of 0.25% bupivacaine hydrochloride solution. Afterward, mice received i.m. injections of 100 ml each of the plasmid DNA vaccines or PBS. Booster injections were given every other week (weeks 3, 5) using the same protocol.
Enzyme-linked immunosorbent assay (ELISA). The amount of anti-GRP Abs and anti-HSP65 Abs in the immune sera was determined using ELISA as described by Guojun et al.
12 using recombinant GFP-GRP10 and HSP65 as immunogens (10 mg per well), respectively. Immunogen coated 96-well flat-bottomed ELISA plates were blocked and then incubated with 100 ml per well of 1:100 diluted sera. A secondary horseradish peroxidaseHRP-conjugated goat anti-mouse immunoglobulin G (Sigma-Aldrich Co., St Louis, MO, USA) was used for the substrate reaction. The absorbance measured at a wavelength of 450 nm is proportional to the GRP-specific or HSP65-specific IgG titers within the sera. Each measurement was carried out in duplicate.
For determination the Abs titers, sera collected at week 9 with different dilutions were test using the ELISA method. Pre-immune serum was used as negative control. Ab titers was defined as the maximum serum dilution that manifested an ELISA optical density (OD) reading that was at least five s.d. greater than the mean OD obtained in wells that contained pre-immune serum.
The method for avidity assays was similar to that described by Pullen et al. 23 Briefly, GFP-GRP10 coated plates were blocked and then incubated with 100 ml per well 1:100 diluted sera. After incubation, wells were washed and incubated with 100 ml of serial dilutions of 0-4 M sodium thiocyanate (NaSCN, Sigma), a chaotropic compound that interferes with antigen-Ab reaction, in PBS. The wells were incubated for 10 min at 37 1C before washing. The remainder of the assay was carried out similar to the ELISA analysis. The relative avidities of Abs were observed based on the concentration of NaSCN required to depress the value of OD 450 to half its initial value.
Expression of vaccine constructs in vitro. A total of 2 mg of DNA plasmids were transfected into 5 Â 10 5 RM-1 cells using Lipofectamine 2000 (Invitrogen Corp.). At 48 h after transfection, 100 ml medium from transfected culture was coated in 96-well flat-bottomed ELISA plates in triplicate. Plates were blocked and then incubated with anti-GRP Abs (affinity purified from GRP anti-sera by N-hydroxysuccinimide (NHS)-activated sepharose 4FF Kit, Pharmacia), and remainder of the assay was carried out similar to the ELISA analysis.
Cell proliferation assay. The effects of the GRP 1À27 full peptide or anti-GRP mAbs on the proliferation of RM-1 cells were measured using the MTT assay. 24 Briefly, RM-1 cells plated on 96-well plates at 1 Â 10 4 cells per well were incubated with serial dilutions of the GRP 1À27 peptide (Sigma), anti-GRP mAbs (affinity purified) or the immune sera for 48 h followed by 20 ml of MTT for 4 h. At the end of the incubation, absorbances were read at 570 nm. All assays were performed in triplicate.
RM-1 cells, incubated in the presence of 0, 12.5 or 50 mg ml -1 affinity purified anti-GRP mAbs for 48 h, 4 cells per well were cultured overnight and then incubated with serial dilutions of anti-GRP or anti-GRPR Abs for 3 h at 37 1C. Guinea pig complement was added at a predetermined final dilution (1/20) in the Ab-containing medium. Cells were incubated for an additional 1 h and then the culture supernatant was separated to measure released lactate dehydrogenase activity. The percentage lysis was calculated as follows: 100À((experimental releaseÀeffector spontaneous releaseÀtarget effector spontaneous release)/(target maximum release-target spontaneous release)). All assays were performed in triplicate.
The therapeutic effect of the immune sera on tumor growth. C57BL/6 male syngeneic mice were s.c. implanted with 2 Â 10 5 RM-1 cells. When tumors became easily palpable, mice were randomly divided into three groups (n ¼ 4). A volume of 100 ml of immune sera (p-HSP65-GRP6-M4) were intravenously injected into mice daily for 10 successive days, whereas the controls received 100 ml injections of PBS or sera from p-HSP65-M2 immunized mice. Tumor dimensions were measured with calipers and the tumor volumes were calculated using the following formula, tumor volume (mm 3 ) ¼ length Â width 2 Â 0.52. Splenocytes proliferation assay. Splenocytes from immunized or PBS-treated mice were freshly isolated, plated at 5 Â 10 5 cells per well in triplicate and stimulated for 72 h with chemo-synthesized hGRP 18À27 , mHSP70 407À426 and ConA at 10 mg ml -1 , 10 mg ml -1 and 1.5 mg ml -1 , respectively. 24 The Splenocyte responses were detected by MTT method.
CTL assay. hGRP 18À27 stimulated splenocytes served as effector cells, while RM-1 cells were used as target cells. cytotoxic T lymphocyte (CTL) assay was carried out with effector and target cells (1 Â 10 4 per well) mixed at varying E/T cell ratios in a final volume of 200 ml. After 5 h incubation, culture supernatant was separated to measure released lactate dehydrogenase activity.
The effect of isolated splenocytes on tumor growth. C57BL/ 6 male syngeneic mice were s.c. implanted with 2 Â 10 5 RM-1 cells. When tumors became easily palpable, mice were randomly divided into two groups (n ¼ 4). One group of mice received intravenous injection of 10 7 splenoctes isolated from p-HSP65-GRP6-M4 immunized mice thrice at day 6, 10 and 14 after tumor cell inoculation, while the controls received that from PBStreated mice instead. Tumor dimensions were measured with calipers and the tumor volumes were calculated.
Immunochemical staining of RM-1 cells. Confluent RM-1 cells on coverslips were fixed by methanol/acetone (1:1, v/v) and permeabilized with 0.1% Triton X-100 in PBS. After blocking, cells were incubated with the purified anti-GRP Abs, anti-GRPR Abs 25 or control Abs (diluted 1:10) for 2 h at 37 1C, followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (diluted 1:400). Coverslips were developed for 20 min at room temperature by using a substrate solution of 0.05% 3,3 0 -diaminobenzidine and 0.012% hydrogen peroxide in 10 mM Tris-HCl (pH 7.5).
Histopahtological observation of tumor and normal tissues. Tumor and normal tissue samples were fixed with 10% formaldehyde and embedded in paraffin according to standard procedures. 4 mm-paraffin sections were cut and stained with hematoxylin and eosin. All sections were evaluated for histopathological changes that could be related to the treatment by an experience pathologist.
Statistical analysis. For comparison of humoral immune response and tumor growth between different groups, the two-tailed Student's t-test was used. Mouse survival data were analyzed using the log-rank test. Data of Ab titers were analyzed by Kruskal-Wallis test (nonparametric analysis of variance) and the Dunn's multiple comparisons test. Differences were considered statistically significant when Po0.05.
